Clinical Trials Logo

Death, Sudden clinical trials

View clinical trials related to Death, Sudden.

Filter by:

NCT ID: NCT00733590 Recruiting - Clinical trials for Heart Failure, Congestive

Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention

PROSe-ICD
Start date: June 2003
Phase:
Study type: Observational

The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pulse generator replacement for primary prevention of SCD (PROSe-ICD) was established to : 1. to gain a better understanding of the biological mechanisms that predispose to SCD 2. to develop readily determined clinical, electrocardiographic, genetic and blood protein markers identify patients with an increased risk of dying suddenly

NCT ID: NCT00729430 Completed - Clinical trials for Myocardial Infarction

Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging

OmegaREMODEL
Start date: August 2008
Phase: Phase 3
Study type: Interventional

Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the body. This study will evaluate a new MRI technique in people who have recently had a heart attack. Researchers will also examine the effect of fish oil supplementation on heart health in study participants.

NCT ID: NCT00692666 Completed - Stroke Clinical Trials

Letigen® and Cardiovascular Morbidity

Start date: May 2006
Phase: Phase 4
Study type: Observational

Letigen® was a combination drug containing ephedrine, an adrenergic agonist with lipolytic and appetite-inhibiting properties. The drug was used as adjuvant treatment of obesity from 1990 and up to 2002 when it was withdrawn from the market by the manufacturer. The basis for this was a number of spontaneous reports about patients that died during treatment with Letigen®. The causal relation has never been addressed. There are only sparse data from randomised studies and the above-mentioned reports are not conclusive. We propose a controlled study based on data from Statistics Denmark that hold a complete copy of the Prescription Register of the Danish Medicines Agency and the Danish Hospital Discharge Register. The aim of the study would be to determine whether there is an excess frequency of deaths and serious cardiovascular events that can not be explained by particular characteristics of users of the drug. A well-known problem in such observational studies is a fundamental incomparability between users and non-users of drugs. In the present setting, it should be expected that use of Letigen® is associated with high BMI, smoking, alcohol abuse, type-2 diabetes, mild hypertension, low physical activity and other indicators of unhealthy lifestyle. Thus, an uncritical comparison between users and non-users of Letigen® regarding serious cardiovascular events will probably show an excess frequency that can not necessarily be attributed to the drug. This problem can be addressed by a special epidemiological technique - the case-crossover design - which is particularly robust to such comparability problems. In brief, only cases should be included. Controls are the same persons at an earlier time, , where the case-defining disease has not yet developed. The exposure of cases will be compared with the exposure of the same persons' case history. To account for the effect of chronic exposure, we also perform, as a secondary analysis, a conventional case-control study nested within the cohort of Letigen users, and employing a risk-set sampling technique.

NCT ID: NCT00673842 Recruiting - Clinical trials for Myocardial Infarction

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

REFINE-ICD
Start date: March 2011
Phase: Phase 3
Study type: Interventional

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

NCT ID: NCT00664807 Completed - Atrial Fibrillation Clinical Trials

Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)

GAME
Start date: April 2008
Phase: Phase 4
Study type: Observational

To generate a list of potential genetic markers that correlate with an increased risk of life-threatening arrhythmias. To evaluate ECG-based risk markers such as heart rate variability and T-wave Alternans for their association with arrhythmic events.

NCT ID: NCT00661128 Active, not recruiting - Clinical trials for Death, Sudden, Cardiac

Genomics of Sudden Cardiac Arrest

GenSCA
Start date: September 2007
Phase:
Study type: Observational

Sudden cardiac arrest (SCA) is a sudden, unexpected loss of heart function. It is a leading cause of death, and more than 400,000 people in the United States die each year as a result of SCA. This study will analyze genetic samples of people who have experienced SCA and people who have not experienced SCA to determine if there is a genetic basis for SCA.

NCT ID: NCT00614718 Completed - Clinical trials for Ventricular Fibrillation

Failure of Chronically Implanted Defibrillator Leads -Incidence and Management

Start date: January 1993
Phase: N/A
Study type: Observational

Comparison of two different approaches to address the problem of malfunctioning ICD-leads. These leads consist of two parts. One that is used for detection of arrhythmias(and pacing if required) (Pace/Sense) and a second part that is used to deliver therapy is needed (Shock-coil). The two approaches compared are: Replacement of the entire lead in case of any lead malfunction versus placement of an additional pace/sense-lead if the shock-coil of the exiting lead was still functional.

NCT ID: NCT00593164 Withdrawn - Clinical trials for Death, Sudden, Cardiac

Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients With Intravenous Infusion of Magnesium Sulfate

Start date: September 2017
Phase: Phase 2
Study type: Interventional

This study will involve the use of therapeutic hypothermia. This prospective cohort pilot study will evaluate the clinical performance of a new device, the ThermoSuit™ System, to achieve therapeutic hypothermia in comatose patients following resuscitation from cardiac arrest, and the impact of the vasodilator, magnesium sulfate, on cooling performance and hemodynamics in these patients. The study hypothesis is that magnesium sulfate will significantly increase the rate of cooling.

NCT ID: NCT00573092 Withdrawn - Clinical trials for Myocardial Infarction

Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

Start date: September 2007
Phase: N/A
Study type: Observational

High blood pressure is one of the most common health problems in the United States. There are many drug treatment options for high blood pressure, but these medications are not always effective. People with treated high blood pressure can still suffer from other serious cardiovascular health problems, including heart attack, sudden death, or stroke. Genetic variations may cause some people to be more susceptible to these cardiovascular outcomes despite treatment. This study will identify new gene regions that may influence the effectiveness of high blood pressure drugs in preventing the above mentioned cardiovascular conditions.

NCT ID: NCT00570947 Completed - Clinical trials for Prevention of Sudden Death

CPR Prescription Program

Start date: December 2007
Phase: N/A
Study type: Interventional

In this study we hope to show that prescriptions provided for CPR Anytime™ to patients who are at risk for or have heart disease at three key locations, can motivate families to learn the skill. We will use our ED sites, an office based primary care setting, and an office based cardiology practice. Participants will be given the pharmacy locations where they can be purchased. Optimally they will complete the program at home with their family. Research Hypothesis: 1. Families of patients at risk for coronary artery disease can be motivated to learn CPR by receiving a prescription for a CPR Anytime ™ self learning kit. 2. As part of the multiplier effect, an additional 1.5 family members per participant are projected to be trained to perform CPR. 3. Families may experience a "teachable moment" when their loved one is in the emergency department. In comparison to the office settings, this may increase the likelihood that they fill the prescription for CPR Anytime® and complete the learning kit.